Ion Beam Applications SA (IOBCF)
Summary
Ion Beam Applications SA (IOBCF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ion Beam Applications SA ever had a stock split?
Ion Beam Applications SA Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Mr. Olivier Legrain CEO | OTC PINK Exchange | BE0003766806 ISIN |
| BE Country | 1,947 Employees | - Last Dividend | 13 Jan 2000 Last Split | - IPO Date |
Overview
Ion Beam Applications SA is an innovative firm dedicated to advancing cancer treatment through the development, manufacturing, and support of medical devices and software solutions. Established in 1986, the company proudly operates on a global scale, with significant presences in Belgium, the United States, among other international locations. Ion Beam Applications SA is structured around two primary business segments: Proton Therapy and Other Accelerators, and Dosimetry. This distinction underscores the company's comprehensive approach, spanning from cutting-edge cancer therapy systems to precise radiation therapy and medical imaging quality assurance solutions. Through strategic partnerships with entities like the SCK CEN (Belgian nuclear research center), University of Pennsylvania, and the Particle Therapy Interuniversity Center Leuven, Ion Beam Applications SA is at the forefront of research and development in its field, notably in the promising area of radioisotope cancer treatment and the innovative ConformalFLASH1 technology.
Products and Services
- Proton Therapy and Other Accelerators
This segment focuses on the development, fabrication, and service of medical and industrial particle accelerators and proton therapy systems. Ion Beam Applications SA provides turnkey solutions that leverage the power of proton beams for cancer treatment, offering a less invasive alternative with the potential for reduced side effects compared to conventional radiation therapy. Additionally, the company produces a range of cyclotrons designed for positron emission tomography (PET) or SPECT radioisotopes production, addressing the needs of nuclear medicine. Industrial accelerators for sterilization and ionization further showcase the company's prowess in developing technology for a variety of critical applications.
- Dosimetry
Ion Beam Applications SA's Dosimetry segment delivers critical solutions and services aimed at enhancing efficiency and minimizing errors in radiation therapy and medical imaging. Quality assurance and calibration procedures are paramount in ensuring the safety and effectiveness of radiation therapy. The company's offerings in this area support healthcare professionals in achieving the highest standards of care, underpinned by precision and reliability.
- Actinium-225 Production Partnership
In collaboration with SCK CEN, Ion Beam Applications SA is pioneering the production of Actinium-225 (225Ac), a next-generation radioisotope touted for its potential to revolutionize cancer treatment. This strategic research and development partnership highlights the company's commitment to exploring innovative treatment options that could offer new hope to patients battling cancer.
- Research in ConformalFLASH
Through an agreement with the University of Pennsylvania and a research partnership with Particle Therapy Interuniversity Center Leuven, Ion Beam Applications SA is deeply involved in the development of ConformalFLASH1, a cutting-edge technology aimed at improving the effectiveness of radiation therapy. Such initiatives underscore the company’s dedication to advancing cancer treatment methodology by exploring and developing technologies that may significantly enhance patient outcomes.
